Trade Gilead Sciences Inc - GILD CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.40 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 76.48 |
| Open | 76.46 |
| 1-Year Change | -0.83% |
| Day's Range | 75.88 - 77.82 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 26, 2024 | 76.65 | -0.14 | -0.18% | 76.79 | 78.23 | 75.45 |
| Jul 25, 2024 | 76.46 | 2.98 | 4.06% | 73.48 | 77.28 | 73.43 |
| Jul 24, 2024 | 73.65 | 3.20 | 4.54% | 70.45 | 74.35 | 70.01 |
| Jul 23, 2024 | 71.12 | -0.88 | -1.22% | 72.00 | 72.34 | 70.73 |
| Jul 22, 2024 | 71.95 | -0.28 | -0.39% | 72.23 | 73.24 | 71.22 |
| Jul 19, 2024 | 72.52 | -0.71 | -0.97% | 73.23 | 74.10 | 71.90 |
| Jul 18, 2024 | 72.95 | 0.28 | 0.39% | 72.67 | 74.86 | 72.36 |
| Jul 17, 2024 | 73.25 | 1.66 | 2.32% | 71.59 | 73.91 | 71.59 |
| Jul 16, 2024 | 71.55 | 0.94 | 1.33% | 70.61 | 71.99 | 69.61 |
| Jul 15, 2024 | 70.76 | 1.21 | 1.74% | 69.55 | 71.18 | 69.15 |
| Jul 12, 2024 | 69.85 | -0.17 | -0.24% | 70.02 | 70.62 | 68.77 |
| Jul 11, 2024 | 69.95 | 1.27 | 1.85% | 68.68 | 70.24 | 67.95 |
| Jul 10, 2024 | 68.65 | 1.26 | 1.87% | 67.39 | 68.80 | 67.39 |
| Jul 9, 2024 | 67.71 | 0.12 | 0.18% | 67.59 | 67.92 | 66.27 |
| Jul 8, 2024 | 67.20 | -0.48 | -0.71% | 67.68 | 68.72 | 66.98 |
| Jul 5, 2024 | 66.40 | 0.08 | 0.12% | 66.32 | 66.88 | 65.96 |
| Jul 3, 2024 | 66.54 | -1.60 | -2.35% | 68.14 | 68.45 | 66.53 |
| Jul 2, 2024 | 67.98 | -0.25 | -0.37% | 68.23 | 68.59 | 67.53 |
| Jul 1, 2024 | 68.45 | 0.34 | 0.50% | 68.11 | 69.94 | 67.95 |
| Jun 28, 2024 | 68.03 | -0.34 | -0.50% | 68.37 | 68.95 | 68.01 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Gilead Company profile
What is Gilead Sciences?
What does the company do?
A research-based biopharmaceutical company, Gilead Sciences, discovers, produces and markets innovative healthcare products that are capable of transforming and simplifying medical care for people, who suffer from life-threatening diseases globally.
A bit of Gilead Sciences’ history
Gilead Sciences was established in June 1987. The company primarily focused on antiviral medicines. It concentrated on gene therapy, estimating the potential of genetic code blockers. The development and research of small molecule antiviral therapeutics started in 1991 with licensing of a group of nucleotide compounds (tenofovir was one of them) that further became widely-used anti-retroviral medicines. In 1990, Gilead collaborated with Glaxo for the development and research of genetic code blockers, known as antisense.
Who founded Gilead Sciences?
Gilead Sciences was founded by Michael L. Riordan, a 29-year-old doctor, who graduated from the Johns Hopkins School of Medicine, Washington University of St. Louis and the Harvard Business School. Riordan worked as the company’s CEO from its inception till 1996.
Current size, team and locations
Headquartered in Foster City, California, US, the company operates across 6 continents and has a team of almost 9,000 employees. Gilead has a portfolio of 24 marketed products and is rapidly expanding. The research and development division works on over 400 clinical studies, evaluating compounds that potentially will become the next generation of efficient medicines.
Quick facts about Gilead Sciences
- Developing access programmes to provide HIV and viral hepatitis medicines at significantly reduced prices in 134 low- and middle-income countries, the company serves approximately 10 million people in the developing world with Gilead’s HIV/AIDS therapies.
- It is said that Riordan wanted to attract Warren Buffett as Gilead’s board member and investor, but was unsuccessful.
- In 2005 the company created the Gilead Foundation, a non-profit organisation that is trying to improve the well-being and health of underserved communities in the United States and globally.
- In 2016 the company gained $30.4 billion in revenue and was ranked the second in the Barron’s 500 rankings. The company also became the first in Business Insider’s list of top companies to work for.
How to learn the Gilead Sciences share price?
Gilead Sciences shares are listed and traded on the NASDAQ stock exchange under the ticker symbol GILD. The company is a component of the US Tech 100, S&P 500 and S&P 100 indices. Join Capital.com to trade CFDs on the Gilead Sciences share price fluctuations and follow the GILD chart in real-time.
| Industry: | Pharmaceuticals (NEC) |
333 Lakeside Dr
FOSTER CITY
CALIFORNIA 94404-1147
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com